|
| |
ALZA CorporationALZA Corporation is the leading provider of drug delivery solutions with the world's broadest array of technology platforms, including oral, transdermal, implantable and liposomal technologies. ALZA partners with pharmaceutical and biotechnology companies to develop and manufacture pharmaceutical products that enhance healthcare for millions of patients worldwide.
ALZA's drug delivery platforms are designed to provide numerous benefits:
Improve efficacy and patient compliance
Reduce side effects
Enhance delivery of compounds with poor solubility or high first-pass metabolism
Address delivery challenges posed by proteins, vaccines, oligonucleotides and biopharmaceuticals
Create unique delivery profiles that meet specific drug therapy requirements
| Contact Details: |
| 1900 Charleston Road, P.O. Box 7210 |
| Mountain View |
| CA |
| 94039-7210 |
| United States of America |
| Tel: | (650) 564-5000 |
| Fax: | (650) 564-7070 |
| Email: | |
| WWW: | www.alza.com/
|
|
Loading...
|
Recent Publications by ALZA Corporation: |  |
[Family doctors and psychiatrists and the patient with depression: the need to re-adjust health care approaches and organisational dynamics]
OBJECTIVES: To find out the perceptions of family doctors (FD) and... | 24th June, 2009
| Centro de Salud de Alza, Donostia, Comarca Ekialde, Osakidetza-Servicio
| Aten Primaria. 2009 Jan;41(1):33-40. Epub 2008 Dec 19.
DOI Direct Link |
Passive absorption of fentanyl from the fentanyl HCl iontophoretic transdermal system.
BACKGROUND: The fentanyl HCl iontophoretic transdermal system (ITS) is a... | 15th April, 2009
| ALZA Corporation, Mountain View, CA, USA.
| Curr Med Res Opin. 2009 Feb;25(2):363-6.
DOI Direct Link |
Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS formulation.
An ALZA OROS drug delivery system was evaluated for its potential to... | 8th April, 2009
| ALZA Corporation, Department of Analytical Development, Mountain View, CA
| Int J Pharm. 2009 Jan 21;366(1-2):74-81. Epub 2008 Sep 17.
DOI Direct Link |
Effect of dapoxetine on the pharmacokinetics and hemodynamic effects of tamsulosin in men on a stable dose of tamsulosin.
The tolerability of dapoxetine, a short-acting selective serotonin... | 24th February, 2009
| Clinical Pharmacology, ALZA Corporation, Mountain View, California USA.
| J Clin Pharmacol. 2008 Dec;48(12):1438-50. Epub 2008 Oct 2.
DOI Direct Link |
Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits.
Dexamethasone is a corticosteroid with proven efficacy for treating both... | 26th September, 2008
| ALZA Corporation, Drug Device R&D, Mountain View, CA 94043, USA.
| J Ocul Pharmacol Ther. 2008 Jun;24(3):301-8.
DOI Direct Link |
→View more ALZA Corporation research publications. |
Press Releases on ALZA Corporation:
|
 |
| Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting |
6th November, 2009 |
Intarcia Therapeutics, Inc. |
HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2
|
| CONCERTA(R) in the Classroom: New Data on Attention in Children With ADHD |
4th November, 2009 |
McNeil Pediatrics(TM) |
LAS VEGAS, Nov. 4 /PRNewswire/ -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that
|
| Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference |
30th September, 2009 |
Intarcia Therapeutics, Inc. |
VIENNA, Sept. 30 /PRNewswire/ -- Intarcia Therapeutics, Inc. today presented final results from its Phase 1b clinical study of ITCA 650 (DUROS® continuous delivery of exenatide) for the treatment of
|
| Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes |
17th September, 2009 |
Intarcia Therapeutics, Inc. |
HAYWARD, Calif., Sept. 17 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the start of enrollment for a phase 2 study comparing its proprietary drug candidate ITCA 650 (DUROS continuous
|
| New Report Just Published: World Prostate Cancer Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Prostate Cancer Therapeutics Market
http://www.reportlinker.com/p0119471/World
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 42 individuals from ALZA Corporation using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 2347 times since April 2007, the link to the organisation's website has been followed 348 times Recent Search Terms used to find this page: ALZA Corporation Background | Alza Corporation | alza corporation website | dapoxetine alza technology oros | alza pharmaceuticals vacaville ca 2008 layoffs | alza pharmaceuticals vacaville ca layoffs | ALZA Corporation for sale | Alza Corporation DE USA | alza sale | alza corporation | . Search for more companies in Mountain View Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for ALZA Corporation |
